"Arctech Innovation is a world-leading innovation centre for breakthrough research, evaluation and commercialisation of new, game-changing products for the surveillance, diagnosis, and control of diseases such as malaria and COVID-19. It is a spin-out company from the London School of Hygiene & Tropical Medicine (LSHTM), co-founded by Professor James Logan, with a world-class team of research scientists with decades of experience in entomology, clinical trials, chemical ecology and microbiology, It has an outstanding global reputation for independent efficacy testing of arthropod control products including mosquito repellents, insecticides, lures, traps and head lice treatments in its Good Laboratory Practice (GLP) compliant laboratories."

During the past decade, ARCTEC conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "ARCTEC" #1 collaborator was "Cardiff University" with 1 trials as a collaborator, "Durham University" with 1 trials as a collaborator and "Medical Detection Dogs" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "ARCTEC" are "Covid19" (1 trials) and "Tick Bites" (1 trials). Many other conditions were trialed in "ARCTEC" in a lesser frequency.

Most popular intervention types in "ARCTEC" are "Behavioral" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Citrepel (Insect Repellent) EPA Reg. No. 84878-2" (1 trials) and "Collection of odour samples" (1 trials). Other intervention names were less common.

The vast majority of trials in "ARCTEC" are 2 trials for "All" genders.

Currently, there are NaN active trials in "ARCTEC". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in ARCTEC, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in ARCTEC, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".